P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833

Blood

Volumn 93, Issue 2, 1999, Pages 599-606

  Egashira, Motoki ^a   Kawamata, Norihiko ^a   Sugimoto, Koichi ^a   Kaneko, Takako ^a   Oshimi, Kazuo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; VALSPODAR;

ARTICLE; CELL LINEAGE; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TRANSPORT KINETICS;

EID: 0033555758     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.2.599.402k06_599_606     Document Type: Article

References (44)

1. Ling V: P-glycoprotein and resistance to anticancer drugs. Cancer 69:2603, 1992
2. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal foundation award lecture. Cancer Res 53:747, 1993
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159, 1989
4. Borst P, Schinkel AH, Smit JJM, Wagenaar E, Deemter LV, Smith AJ, Eudems EWHM, Bass F, Zaman GJR: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoprotein in mammals. Pharmacol Ther 60:289, 1993
5. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85, 1991
6. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451, 1994
7. Chaudhary PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprolein in human peripheral blood lymphocytes. Blood 80:2735, 1992
8. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729, 1992
9. Yamamoto T, Iwasaki T, Watanabe N, Oshimi K, Naito M, Tsuruo T, Kobayashi Y: Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood 81:1342, 1993
10. + non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966, 1997
11. + large granular lymphocyte proliferative disorders (GLPD). Br J Haematol 87:112, 1994
12. Lamy T, Drenou B, Fardel O, Amiot L, Grulois I, Le Prise PY, Loughran TP, Fauchet R: Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol 100:509, 1998
13. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967, 1981
14. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730, 1982
15. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, Tsuruo T: Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 35:271, 1995
16. Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T: Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother Pharmacol 29:195, 1992
17. Watanabe T, Tsuge H, Oh-hara T, Naito M, Tsuruo T: Comparative study on reversal efficacy of SDZ PDC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34:235, 1995
18. List AF, Spier C, Geer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652, 1993
19. Moore DF, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F: Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: A phase II study. Clin Oncol 7:300, 1995
20. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, Kapel J, Groenewegen A, Charnick S, Zittoun R, Lowenberg B: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10:1741, 1996
21. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Williams GS, Kantaijian H, Keating M, Newman RA, Andreeff M: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15:1796, 1997
22. Gong JH, Maki G, Klingemann HG: Characterization of human cell line (NK92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652, 1994
23. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J: Characterization of a cell line, NKL, derived from an aggressive human natural killer leukemia. Exp Hematol 24:406, 1996
24. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB: Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160, 1990
25. Oguri T, Fujiwara Y, Isobe T, Katoh O, Watanabe H, Yamakido M: Expression of γ-glutamylcysteine synthetase (γ-GCS) and multi-drug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 77:1089, 1998
26. Kawamata N, Nakamura Y, Miki T, Sato E, Isobe Y, Furusawa S, Hirosawa S, Oshimi K: Detection of chimaeric transcripts of the immunoglobulin heavy chain and BCL6 genes by reverse-transcriptase polymerase chain reaction in B-cell non-Hodgkin's lymphomas. Br J Haematol 100:484, 1998
27. Oshimi K, Yamada O, Kaneko T, Nishinarita S, Iizuka Y, Urabe A, Inamori T, Asano S, Takahashi S, Hattori M, Naohara T, Ohira Y, Togawa A, Masuda Y, Okubo Y, Furusawa S, Sakamoto S, Omine M, Mori M, Tatsumi E, Mizoguchi H: Laboratory findings and clinical courses of 33 patients with glanular lymphocyte-proliferative disorders. Leukemia 7:782, 1993
28. Kaneko T, Fukuda J, Yoshihara T, Zheng H, Mori S, Mizoguchi H, Oshimi K: Nasal natural killer (NK) cell lymphoma: Report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. Br J Haematol 91:355, 1995
29. Oshimi K: Lymphoproliferative disorders of natural killer cells. Int J Hematol 63:279, 1996
30. Nagler A, Lanier LL, Cwirla S, Philips JH: Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183, 1989
31. Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, Rosen N, Fojo AT: Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem 264:18031, 1989
32. Bates SE, Mickley LA, Chen YN, Richert N, Rudick J, Biedler J, Fojo AT: Expression of a drug resistance gene in human neuroblastoma cell lines: Modulation by retinoic acid-induced differentiation. Mol Cell Biol 9:4337, 1989
33. Spits H, Lanier LL, Phillips JH: Development of human T and natural killer cells. Blood 85:2654, 1995
34. - cases. Blood 86:2329, 1995
35. Kobayashi Y, Yamashiro T, Nagatake H, Yamamoto T, Watanabe N, Tanaka H, Shigenobu K, Tsuruo T: Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52. Biochem Pharmacol 48:1641, 1994
36. Chong ASF, Markham PN, Gebel HM, Bines SD, Coon JS: Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 36:133, 1993
37. Treichel RS, Olken S: The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines. Int J Cancer 50:305, 1992
38. Klimecki WT, Taylor CW, Dalton WS: Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol 15:152, 1995
39. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H: Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-γ in normal human T lymphocytes. Blood 88:1747, 1996
40. Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C, Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem 272:5974, 1997
41. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992
42. Paulusma CC, Bosma PJ, Zaman GJR, Bakker CTM, Otter M, Scheffer GL, Scheper RJ, Borst P, Elferink RPJO: Conjenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126, 1996
43. Kool M, Haas M, Scheffer GL, Scheper RJ, Eijk MJT, Juijn A, Bass F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, MRP5, homologues of the multidrug resistance-associated protein gene (MRP1). in human cancer cell lines. Cancer Res 57:3537, 1997
44. Scheffer GL, Wingaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nature Med 1:578, 1995